On March 11, the National Health Commission issued the application scheme for covid-19 virus antigen detection (Trial). It is mentioned that if community residents have self-test needs, they can purchase antigen detection reagents for self-test through retail pharmacies, online sales platforms and other channels.
Because of its fast and convenient advantages, antigen detection can speed up the large-scale screening of residents in sealed and controlled areas, reduce the cost of government epidemic prevention and control, and shorten the isolation time of relevant epidemic areas. Industry insiders generally believe that the implementation of the plan marks the opening of covid-19 antigen home self-test policy in China, and China’s antigen detection reagent is expected to usher in a market of 100 billion yuan.
According to the theme database of financial Associated Press, among the relevant listed companies:
Nanjing Vazyme Biotech Co.Ltd(688105) independently developed and produced corresponding PCR series and qPCR series biological reagents, which can be used as key raw materials for the production of covid-19 nucleic acid detection reagents. It is one of the main suppliers of key raw materials of covid-19 nucleic acid detection reagents in China.
Bgi Genomics Co.Ltd(300676) holding subsidiary Huada has recently obtained the document of the people’s Republic of China on the change of medical device registration (in vitro diagnostic reagent) issued by the State Food and drug administration. At present, the company has reached cooperation with Jointown Pharmaceutical Group Co.Ltd(600998) and other companies and will vigorously promote the covid-19 antigen detection reagent.
